NeoTCR-T Technology Platform for Preclinical ACT Development

Empowering researchers to bridge the gap between "omics" data and high-resilience T-cell therapy. Our platform integrates advanced neoantigen discovery, high-resolution TCR profiling, and longitudinal in vivo assessment to ensure your ACT candidates maintain functional persistence in complex tumor environments.

Strategic Overview: Solving the Bottlenecks of Neoantigen-Specific ACT

Precision NeoTCR-T Engineering for Personalized Immunotherapy Research

T-cell receptor engineered T cell (TCR-T) therapy represents a major leap in adoptive cell transfer (ACT). By targeting tumor-specific neoantigens, researchers can exploit the immune system's natural ability to distinguish mutant cells from healthy tissue with absolute specificity. However, the path from mutation discovery to a functional TCR-T candidate is fraught with technical hurdles, including low precursor frequencies in peripheral blood and the premature exhaustion of highly activated T cells.

Recent scientific guidelines emphasize that the success of a NeoTCR-T program depends on three pillars: 1) the sensitivity of discovery tools, 2) the fidelity of the TCR activation profile, and 3) the resilience of the final engineered product under chronic antigen exposure. Creative Biolabs provides the expertise to optimize these pillars through an entity-agnostic approach.

Technical Barrier Analysis: Traditional TCR-T development often fails because it over-prioritizes high-avidity clones that eventually lead to hyperresponsivity and activation-induced cell death (AICD). Our strategy, backed by the latest high-resolution profiling research, focuses on identifying clones with moderate stimulation signatures that show superior anti-tumor responses during repeated tumor rechallenge.

Core Preclinical Objectives Supported by Our Platform:
Systematic discovery of rare, tumor-restricted TCR clonotypes from blood or metastatic lysates.
Comparative transcriptomic profiling of TCR activation states to predict in vivo persistence.
Engineering TCR-T cells with balanced structural avidity for multi-entity anti-tumor activity.

Preclinical End-to-End NeoTCR-T Service Modules

Our modular service architecture allows researchers to plug into any stage of the NeoTCR-T pipeline, from initial target discovery to longitudinal in vivo validation.

Service Module	Detailed Technical Description	Service Highlights
Targeting Neoepitope discovery & Validation	Identification of somatically mutated ligands via LC-MS/MS and proprietary in silico prediction models. We support HLA-matched B-cell lymphoma and melanoma cell line minigene construction for precise epitope presentation.	• MS-validated epitope mapping • HLA-A03/B27 specific models • Minigene engineering
Profiling High-Res Activation Characterization	Integrating transcriptomic profiling and immune repertoire sequencing at individual cell resolution following antigen-specific restimulation. We perform clustering based on GZMA, LAG3, and TIGIT expression to distinguish cytotoxic, inhibitory, and proliferative states of each clonotype.	• Cell-level GEX/VDJ integration • CD137+ activation enrichment • Trajectory analysis for T-cell fate
Synthesis TCR Optimization & Engineering	Retroviral or site-specific orthotopic TCR replacement (OTR) into the TRAC locus. We offer sequence optimization, including murinized constant regions and cysteine bridge introduction, to maximize TCR surface density and prevent mispairing.	• TRAC-locus orthotopic insertion • TCRmu density quantification • Retroviral/Lentiviral transduction
Longevity Resilience & Rechallenge Assessment	Measuring T-cell performance under chronic antigen pressure using in vitro real-time impedance-based killing monitoring and in vivo xenograft rechallenge models. We analyze IL-10 protective signaling and memory preservation.	• Repeated tumor challenge models • Longitudinal killing assays • Cytokine polyfunctionality index

Optimized Preclinical NeoTCR-T Development Workflow

Integrated workflow diagram for preclinical NeoTCR-T development covering target mapping to resilience validation

Phase 1 — Neoepitope Identification & Target Mapping

We begin by screening tumor-normal sequencing data to identify somatic point mutations. These candidates are validated via LC-MS/MS of HLA peptide complexes to ensure natural presentation. We then construct HLA-matched target cell lines (e.g., U698M lymphoma) expressing tandem minigenes encoding the mutated epitopes.

Phase 2 — Antigen-Specific scTCR Discovery

PBMCs or TILs are specifically restimulated with validated neoantigens. CD137+ activated T cells are magnetically enriched and expanded. We then deploy combined unit-level GEX and scTCR-seq to capture the full V(D)J repertoire of reactive clones, identifying rare but potent TCR sequences even at ultra-low precursor frequencies.

Phase 3 — High-Resolution Functional Ranking

Each identified clonotype undergoes transcriptomic profiling to determine its activation signature. We rank TCRs not just by functional avidity ($EC_{50}$) but by their molecular state. This stage distinguishes between "exhaustion-prone" strong activators and "resilience-ready" moderate activators, providing a data-driven basis for lead candidate selection.

Phase 4 — Orthotopic & Viral TCR Engineering

Lead TCR sequences are optimized (codon optimization, cysteine bridging, murinization) and synthesized. We offer two parallel engineering paths: retroviral transduction for high-throughput screening or orthotopic TCR replacement (OTR) via nuclease-mediated genome editing into the TRAC locus to achieve near-physiological regulation and eliminate chain mispairing.

Phase 5 — Longitudinal Persistence & Resilience Validation

The final engineered TCR-T cells are tested in a xenograft rechallenge model. We mimic chronic antigen exposure by generating TIL products (TIL-P) from primary tumor explants and re-injecting them into secondary tumor-bearing hosts. This ensures the selection of TCRs that maintain cytotoxicity and IL-10 mediated resilience over multiple challenge cycles.

Preclinical Proprietary Technology Platforms

High-Precision Neoantigen Discovery Engine

Utilizing multi-omics integration and LC-MS/MS immunopeptidomics to identify naturally presented mutated ligands on tumor cells, ensuring highly accurate therapeutic target selection.

Cell-level TCR High-Resolution Profiling Platform

Simultaneous assessment of V(D)J clonotype frequency and global gene expression at the cell-level level to identify TCRs with optimal activation/exhaustion ratios.

Preclinical TCR-T Resilience Assessment Platform

Specialized in vivo models designed for repeated tumor challenge, providing longitudinal data on T-cell functional persistence, memory preservation, and therapeutic durability.

Research Insight: Moderate TCR Activation Links to Increased Resilience

High-Resolution Profiling of Neoantigen-Specific TCR Activation

The following insights are derived from a high-resolution analysis of neoantigen-specific T-cells (neoTCRs) from melanoma patients, revealing that intrinsic TCR characteristics qualitatively determine in vivo persistence.¹

Heterogeneous Activation Spectrum: TCRs recognizing a common neoepitope (e.g., KIF2C^P13L) demonstrate a broad spectrum of activation, from "initially strong" activators to "moderately activated" clonotypes.
Strong vs. Moderate Profiles: TCRs with initially strong activation signatures often upregulate inhibitory receptors (LAG3, TIGIT) and proinflammatory markers (XCL1, CCL3) early on, leading to functional impairment during repeated stimulation.
Protective Resilience of Moderate TCRs: In contrast, TCRs with moderate stimulation signatures (like KIF-P2) show superior anti-tumor control in vivo upon repeated rechallenge. This resilience is associated with the upregulation of the anti-inflammatory cytokine IL-10.
Structural Avidity Compensation: Some rare TCRs (like KIF-P1) exhibit increased structural avidity (9-fold increase in k_off rate) which may compensate for low surface expression, allowing for potent in vivo killing capacity.
Strategic Implications: For therapeutic engineering, TCR selection must look beyond simple functional avidity (EC₅₀) and prioritize clonotypes with moderate activation patterns that correlate with sustained long-term tumor control.

Comparable in vivo primary tumor rejection by neoTCR‑tg T cells despite distinct activation profiles.

Fig. 1 NeoTCR‑tg T cells exhibit comparable primary tumor rejection in vivo irrespective of activation patterns.^1,2

Technical FAQ

Peripheral blood-derived T-cells are often in a less exhausted state compared to tumor-infiltrating lymphocytes (TILs), which are frequently dysfunctional due to the immunosuppressive TME. Peripheral blood provides access to a "cleaner" TCR repertoire for high-resilience cloning.

Moderate activation avoids the rapid induction of inhibitory programs (PD-1, LAG-3) and AICD. This allows the T-cells to maintain functional cytotoxic capacity over multiple rounds of antigen stimulation, preventing premature clonal exhaustion.

We utilize real-time cell analysis (RTCA) to monitor impedance-based killing kinetics and perform repeated antigen loading assays. We also measure IL-10 secretion and memory markers (CD45RA/RO) following multi-cycle killing.

Yes. We specialize in orthotopic TCR replacement (OTR) via nuclease-mediated genome editing. By knocking the neoTCR into the TRAC locus, we ensure near-physiological expression and stability, which is often superior to random viral integration.

Our optimized rapid expansion protocols (REP) and engineering pipelines significantly shorten construction time. Typical preclinical preparation for lead candidates ranges from 4 to 8 weeks following sequence identification.